辅助化疗的使用显着降低了早期乳腺癌患者的复发风险并提高了总生存期（OS）。然而，关于激素受体阳性/HER2阴性（HR/HER2-）乳腺癌患者不同辅助化疗方案和方案的疗效的数据很少。我们的目的是总结关于基于蒽环类药物的辅助化疗和剂量密集方案在该人群中的疗效的现有证据。此外，还讨论了当前早期 HR/HER2- 乳腺癌患者治疗中存在的争议。评估在基于紫杉烷的化疗中添加蒽环类药物的作用的患者水平荟萃分析显示，复发率降低了 14%。接受蒽环类药物治疗的患者中，相对风险（RR）0.86，P = 0.0004。评估不同化疗方案作用的患者水平荟萃分析表明，使用辅助剂量密集化疗与显着降低乳腺癌复发和乳腺癌死亡率。新辅助治疗方面的证据较少。对于高危 HR /HER2- 乳腺癌患者，（新）辅助蒽环类和紫杉烷类化疗以及剂量密集方案仍应被视为标准治疗。然而，对于中低风险乳腺癌患者，可以考虑采用无蒽环类药物治疗方案。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Use of adjuvant chemotherapy significantly reduced the risk of recurrence and improved overall survival (OS) in patients with early-stage breast cancer. However few data are available on efficacy of different adjuvant chemotherapy regimens and schedules in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. We aim to summarize the available evidence on efficacy of adjuvant anthracycline-based chemotherapy and of the dose-dense schedule in this population. Moreover, current controversies in the management of patients with early-stage HR+/HER2- breast cancer are discussed.Patient-level meta-analysis evaluating the role of the addition of anthracycline to taxane-based chemotherapy showed that recurrence rate was 14% lower [relative risk (RR) 0.86, P = 0.0004] among patients receiving anthracycline-based treatment.Patient-level meta-analysis evaluating the role of different schedules of chemotherapy administration showed that the use of adjuvant dose-dense chemotherapy is associated with significant reduction in breast cancer recurrences and breast cancer mortality. Less evidence is available in the neoadjuvant setting.For patients with high-risk HR+/HER2- breast cancer, (neo) adjuvant anthracycline and taxane-based chemotherapy, and a dose-dense regimen should still be considered the standard of care. However, in patients with intermediate-low risk breast cancer anthracycline-free regimens could be considered an option of treatment.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.